Free Trial
NYSE:BLCO

Bausch + Lomb (BLCO) Stock Price, News & Analysis

Bausch + Lomb logo
$19.32 -0.06 (-0.31%)
(As of 09:33 AM ET)

About Bausch + Lomb Stock (NYSE:BLCO)

Key Stats

Today's Range
$19.32
$19.41
50-Day Range
$15.56
$20.93
52-Week Range
$13.16
$21.69
Volume
1,117 shs
Average Volume
560,638 shs
Market Capitalization
$6.80 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.91
Consensus Rating
Moderate Buy

Company Overview

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.

Bausch + Lomb Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
48th Percentile Overall Score

BLCO MarketRank™: 

Bausch + Lomb scored higher than 48% of companies evaluated by MarketBeat, and ranked 515th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Bausch + Lomb has received a consensus rating of Moderate Buy. The company's average rating score is 2.58, and is based on 7 buy ratings, 5 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Bausch + Lomb has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Bausch + Lomb's stock forecast and price target.
  • Earnings Growth

    Earnings for Bausch + Lomb are expected to grow by 42.37% in the coming year, from $0.59 to $0.84 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Bausch + Lomb is -18.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Bausch + Lomb is -18.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Growth Ratio

    Bausch + Lomb has a PEG Ratio of 1.91. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Bausch + Lomb has a P/B Ratio of 1.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Bausch + Lomb's valuation and earnings.
  • Percentage of Shares Shorted

    2.89% of the float of Bausch + Lomb has been sold short.
  • Short Interest Ratio / Days to Cover

    Bausch + Lomb has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Bausch + Lomb has recently decreased by 26.32%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Bausch + Lomb does not currently pay a dividend.

  • Dividend Growth

    Bausch + Lomb does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.89% of the float of Bausch + Lomb has been sold short.
  • Short Interest Ratio / Days to Cover

    Bausch + Lomb has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Bausch + Lomb has recently decreased by 26.32%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Bausch + Lomb has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Bausch + Lomb this week, compared to 4 articles on an average week.
  • Search Interest

    Only 5 people have searched for BLCO on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Bausch + Lomb insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.15% of the stock of Bausch + Lomb is held by insiders.

  • Percentage Held by Institutions

    Only 11.07% of the stock of Bausch + Lomb is held by institutions.

  • Read more about Bausch + Lomb's insider trading history.
Receive BLCO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bausch + Lomb and its competitors with MarketBeat's FREE daily newsletter.

BLCO Stock News Headlines

Brokerages Set Bausch + Lomb Co. (NYSE:BLCO) Price Target at $20.91
This Bull Market Indicator called NVDA at $116
Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…
Bausch + Lomb Sees Strong Growth in Q3 2024
Bausch + Lomb Announces Third-Quarter 2024 Results
See More Headlines

BLCO Stock Analysis - Frequently Asked Questions

Bausch + Lomb's stock was trading at $17.06 on January 1st, 2024. Since then, BLCO shares have increased by 13.7% and is now trading at $19.39.
View the best growth stocks for 2024 here
.

Bausch + Lomb Co. (NYSE:BLCO) released its quarterly earnings results on Wednesday, October, 30th. The company reported $0.17 EPS for the quarter, beating analysts' consensus estimates of $0.16 by $0.01. The business's quarterly revenue was up 18.8% compared to the same quarter last year.

Bausch + Lomb (BLCO) raised $788 million in an IPO on Friday, May 6th 2022. The company issued 35,000,000 shares at $21.00-$24.00 per share.

Top institutional investors of Bausch + Lomb include Maple Rock Capital Partners Inc. (1.03%), Goldentree Asset Management LP (0.95%), River Road Asset Management LLC (0.57%) and Whitebox Advisors LLC (0.35%).
View institutional ownership trends
.

Shares of BLCO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Bausch + Lomb investors own include PayPal (PYPL), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Walt Disney (DIS), Intel (INTC) and Devon Energy (DVN).

Company Calendar

Last Earnings
10/30/2024
Today
11/21/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
2/19/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Ophthalmic goods
Sub-Industry
Medical Equipment
Fax
N/A
Employees
13,300
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$20.91
High Stock Price Target
$26.00
Low Stock Price Target
$17.00
Potential Upside/Downside
+7.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.58
Research Coverage
12 Analysts

Profitability

Net Income
$-260,000,000.00
Pretax Margin
-6.00%

Debt

Sales & Book Value

Annual Sales
$4.68 billion
Cash Flow
$1.88 per share
Book Value
$19.72 per share

Miscellaneous

Free Float
351,644,000
Market Cap
$6.83 billion
Optionable
Optionable
Beta
0.46
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

This page (NYSE:BLCO) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners